Seres therapeutics announces completion of vowst™ asset sale to sociÉtÉ des produits nestlÉ s.a

Transaction supports further development of ser-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections
MCRB Ratings Summary
MCRB Quant Ranking